CompletedPhase 3NCT04334759
DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
Studying Pleural mesothelioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- PrECOG, LLC.
- Principal Investigator
- Patrick Forde, MDJohns Hopkins University
- Intervention
- Durvalumab(drug)
- Enrollment
- 214 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2025
Study locations (30)
- University of California San Diego, La Jolla, California, United States
- University of Miami, Miami, Florida, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- Emory University, Atlanta, Georgia, United States
- University of Chicago, Chicago, Illinois, United States
- NorthShore University Health System/Kellogg Cancer Center, Evanston, Illinois, United States
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
- Massaschusetts General Hospital, Boston, Massachusetts, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, United States
- Morristown Medical/Atlantic Health, Morristown, New Jersey, United States
- Jersey Shore University Medical Center, Neptune City, New Jersey, United States
- Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
- Memorial Sloan Kettering, New York, New York, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
AstraZeneca · Thoracic Oncology Group Australasia (TOGA) · University of Sydney
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04334759 on ClinicalTrials.govOther trials for Pleural mesothelioma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07192900Fast TILs to Treat Metastatic Cancer Patients With Pleural DiseaseDavid Bartlett, MD
- RECRUITINGNANCT07126509Partial Pleurectomy (Surgery) for Unresectable Pleural MesotheliomaUniversity of Chicago
- RECRUITINGPHASE1, PHASE2NCT07121374NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility StudyUniversity Hospital, Antwerp
- RECRUITINGPHASE1NCT06885697Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including MesotheliomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06840834Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and ChemotherapyIntergroupe Francophone de Cancerologie Thoracique
- RECRUITINGPHASE2NCT06875076Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural MesotheliomaThe First Hospital of Jilin University
- RECRUITINGPHASE2NCT06790082The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural MesotheliomaAalborg University Hospital
- RECRUITINGPHASE1NCT06566079Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid TumorsInSilico Medicine Hong Kong Limited